TY - JOUR
T1 - CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) Trial
T2 - Long-Term Follow-Up Results
AU - Notten, Pascale
AU - de Smet, Andre A. E. A.
AU - Tick, Lidwine W.
AU - van de Poel, Marlene H. W.
AU - Wikkeling, Otmar R. M.
AU - Vleming, Louis-Jean
AU - Koster, Ad
AU - Jie, Kon-Siong G.
AU - Jacobs, Esther M. G.
AU - Ebben, Harm P.
AU - Coppens, Michiel
AU - ten Cate, Hugo
AU - Wittens, Cees H. A.
AU - ten Cate-Hoek, Arina J.
N1 - Funding Information:
The CAVA trial was originally funded by a grant from ZonMw (The Netherlands Organisation for Health Research and Development, project number 171101001) and additional funding was provided by the board of the Maastricht University Medical Centre. The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
Dr Coppens reports grants and personal fees from Bayer Daiichi Sankyo, CSL Behring; grants from Boehringer Ingelheim, Pfizer, Bristol-Meyers Squibb, and Sanquin Blood Supply; and personal fees from Sobi, NovoNordisk, and UniQure, outside the submitted work. Dr ten Cate reports personal fees and other from Bayer; other from Pfizer and Coagulation profile; and personal fees from LEO Pharma, Gideon Pharmaceuticals, and Alveron Pharma, outside the submitted work. Dr Wittens reports grants from BTG International Group during the conduct of the study. None of the above-mentioned organizations had any involvement in the design, conduct, analysis, or report of the study data. The remaining authors have no disclosures to report.
Funding Information:
The CAVA trial was funded by a grant from ZonMw (The Netherlands Organisation for Health Research and Development, project number 171101001) and additional funding was provided by the board of the Maastricht University Medical Centre. The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors involved in analyzing the data (P.N. and A.t.C.H.) had full access to all of the data in the study. The corresponding author had final responsibility for the decision to submit for publication.
Publisher Copyright:
© 2021 The Authors.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - BACKGROUND: The CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome) trial did not show a reduction of post-thrombotic syndrome (PTS) after additional ultrasound-accelerated catheter-directed thrombolysis in patients with acute iliofemoral deep vein thrombosis at 1-year follow-up. This prespecified analysis of the CAVA trial aimed to determine the impact of additional thrombolysis on outcomes of PTS at long-term follow-up.METHODS AND RESULTS: Patients aged 18 to 85 years with a first-time acute iliofemoral deep vein thrombosis were included and randomly assigned (1:1) to either standard treatment plus ultrasound-accelerated catheter-directed thrombolysis or standard treatment alone. The primary outcome was the proportion of PTS (Villalta score >= 5 on 2 occasions >= 3 months apart or venous ulceration) at the final follow-up visit. Additionally, PTS according to the International Society on Thrombosis and Haemostasis (ISTH) consensus definition was assessed to allow external comparability. Major bleedings were the main safety outcome. At a median follow-up of 39.0 months (interquartile range, 23.3-63.8), 120 patients (79.8%) participated in the final follow-up visit: 62 from the intervention group and 58 from the standard treatment group. PTS developed in 19 (30.6%) versus 26 (44.8%) patients, respectively (odds ratio [OR], 0.54; 95% CI, 0.26 to 1.15 [P=0.11]), with an absolute difference between groups of -14.2% (95% CI, -32.0% to 4.8%). Using the ISTH consensus definition, a significant reduction in PTS was observed (29 [46.8%] versus 40 [69.0%]) (OR, 0.40; 95% CI, 0.19-0.84 [P=0.01]) with an absolute difference between groups of -22.2% (95% CI, -39.8% to -2.8%). No new major bleedings occurred following the 12-month follow-up.CONCLUSIONS: The impact of additional ultrasound-accelerated catheter-directed thrombolysis on the prevention of PTS was found to increase with time. Although this study was limited by its sample size, the overall findings indicate a reduction of mild PTS without impact on quality of life.
AB - BACKGROUND: The CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome) trial did not show a reduction of post-thrombotic syndrome (PTS) after additional ultrasound-accelerated catheter-directed thrombolysis in patients with acute iliofemoral deep vein thrombosis at 1-year follow-up. This prespecified analysis of the CAVA trial aimed to determine the impact of additional thrombolysis on outcomes of PTS at long-term follow-up.METHODS AND RESULTS: Patients aged 18 to 85 years with a first-time acute iliofemoral deep vein thrombosis were included and randomly assigned (1:1) to either standard treatment plus ultrasound-accelerated catheter-directed thrombolysis or standard treatment alone. The primary outcome was the proportion of PTS (Villalta score >= 5 on 2 occasions >= 3 months apart or venous ulceration) at the final follow-up visit. Additionally, PTS according to the International Society on Thrombosis and Haemostasis (ISTH) consensus definition was assessed to allow external comparability. Major bleedings were the main safety outcome. At a median follow-up of 39.0 months (interquartile range, 23.3-63.8), 120 patients (79.8%) participated in the final follow-up visit: 62 from the intervention group and 58 from the standard treatment group. PTS developed in 19 (30.6%) versus 26 (44.8%) patients, respectively (odds ratio [OR], 0.54; 95% CI, 0.26 to 1.15 [P=0.11]), with an absolute difference between groups of -14.2% (95% CI, -32.0% to 4.8%). Using the ISTH consensus definition, a significant reduction in PTS was observed (29 [46.8%] versus 40 [69.0%]) (OR, 0.40; 95% CI, 0.19-0.84 [P=0.01]) with an absolute difference between groups of -22.2% (95% CI, -39.8% to -2.8%). No new major bleedings occurred following the 12-month follow-up.CONCLUSIONS: The impact of additional ultrasound-accelerated catheter-directed thrombolysis on the prevention of PTS was found to increase with time. Although this study was limited by its sample size, the overall findings indicate a reduction of mild PTS without impact on quality of life.
KW - catheter-directed thrombolysis
KW - Iliofemoral deep vein thrombosis
KW - long-term follow-up
KW - post-thrombotic syndrome
KW - quality of life
KW - QUALITY-OF-LIFE
KW - NONINVASIVE VENOUS EXAMINATIONS
KW - DEEP-VEIN THROMBOSIS
KW - CLINICAL INVESTIGATIONS
KW - 1ST EPISODE
KW - VALIDATION
KW - DISEASE
KW - LEG
KW - DETERMINANTS
KW - TRANSLATION
U2 - 10.1161/JAHA.120.018973
DO - 10.1161/JAHA.120.018973
M3 - Article
C2 - 34032127
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 11
M1 - 018973
ER -